Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) announced that CEO Thomas K. Equels authored a new article in Breaking Defense titled “Biodefense is force protection: Ready today, prepared for tomorrow,” published August 11, 2026. Equels argues that biodefense should be integrated into military force protection planning, with broad-spectrum prophylactic and early-onset antiviral countermeasures evaluated before novel biological threats emerge.
The article highlights government-funded preclinical studies of AIM’s investigational drug Ampligen (rintatolimod). Research at USAMRIID reported a rintatolimod-treated mouse cohort with 100% survival in a lethal Ebola model versus 100% mortality in controls, supporting further mechanism-of-action evaluation across Ebola variants. Additional preclinical work at Utah State University following the 2003 SARS outbreak supported further evaluation of Ampligen as a potential early-onset antiviral against SARS-related coronaviruses.
AIM ImmunoTech (NYSE American: AIM) reported second quarter 2026 results and operational progress centered on advancing Ampligen toward a planned Phase 3 trial in metastatic pancreatic cancer. The company completed enrollment and Ampligen dosing in the Phase 2 DURIPANC study combining Ampligen with Imfinzi (durvalumab), and engaged Thermo Fisher Scientific's PPD clinical research business to support Phase 3 study design.
AIM highlighted encouraging observations from Erasmus MC Cancer Institute, including favorable safety and survival trends, and continued focus on pancreatic cancer as its strategic priority. As of June 30, 2026, cash and equivalents were $9.9 million versus approximately $3.0 million at year-end 2025. Q2 2026 research and development expenses were about $589,000 (down from $1.2 million a year earlier), while general and administrative expenses rose to about $2.9 million (from $1.5 million). Net loss was approximately $(3.8 million), or $(0.43) per share, compared to $(2.8 million), or $(3.68) per share, in Q2 2025. The company also regained full compliance with NYSE American listing standards and is planning government-focused initiatives to explore Ampligen's antiviral potential against Ebola via non-dilutive funding.
AIM ImmunoTech (NYSE American:AIM) released a new CEO Corner segment featuring CEO Thomas Equels discussing momentum in its pancreatic cancer program centered on Ampligen.
He reviews the DURIPANC Phase 2 study with Imfinzi, completed enrollment and dosing, encouraging interim observations, safety findings, Phase 3 planning, AstraZeneca/Erasmus collaboration, IP expansion and potential in immunologically “cold” tumors.
AIM ImmunoTech (NYSE American:AIM) reported progress in its pancreatic cancer program centered on Ampligen, a TLR3 agonist in the Phase 2 DURIPANC trial with Imfinzi for metastatic disease.
The company completed enrollment and final dosing, reports encouraging safety, strengthened IP and balance sheet, regained NYSE American compliance, and sees 12 months of potential value catalysts, including primary endpoint analysis starting December 2026 and topline results expected in Q1 2027.
AIM ImmunoTech (NYSE American:AIM) will present in the Webull Corporate Connect Webinar Series, held virtually June 24–25, 2026.
The live webcast is scheduled for Wednesday, June 24, 2026, from 2:40–3:00 PM ET, presented by CEO Thomas Equels. Registration is available online.
AIM ImmunoTech (NYSE American: AIM) reported a key milestone in its Phase 2 DURIPANC study in metastatic pancreatic cancer: the final subject has received a first dose of Ampligen plus Imfinzi.
Primary endpoint analysis is anticipated in December 2026, with topline results in Q1 2027 and secondary endpoint analyses from June 2027.
AIM ImmunoTech (NYSE American: AIM) regained compliance with NYSE American continued listing standards for stockholders’ equity.
Through May–June 2026 warrant exercises and equity offerings, AIM raised about $8.5 million/b] in gross proceeds and believes stockholders’ equity now exceeds the
AIM ImmunoTech (NYSE American: AIM) entered definitive agreements for a registered direct offering and concurrent private placement priced at-the-market for approximately $2.65 million in gross proceeds.
The company will issue 2,554,119 registered shares, 2,554,119 unregistered shares or pre-funded warrants, and Class J warrants for up to 10,216,476 shares to fund clinical manufacturing, current and planned Phase 3 trials, and working capital.
AIM (NYSE American:AIM) reported positive mid-year interim progress from the Phase 2 DURIPANC study evaluating Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX.
The final patient has been enrolled, and AIM remains on track for a planned December 2026 evaluation of the primary endpoint, Clinical Benefit Rate (CBR) at 6 months. DURIPANC follows a 57-subject Named Patient Program where Ampligen monotherapy was associated with median survival of 19.7 months versus 8.6 months for standard of care, with reported quality-of-life improvements.
In NPP subjects with Neutrophil/Lymphocyte ratios <4.5, overall median survival was 34.8 months versus 12.5 months for historical controls. AIM is planning a potential pivotal Phase 3 trial of Ampligen with a PD-1 inhibitor focused on overall and progression-free survival.
AIM ImmunoTech (NYSE American:AIM) released a Virtual Investor “What This Means” video discussing Ampligen in Ebola virus disease preparedness, especially the Bundibugyo (BDBV) strain.
Management reviews preclinical Biosafety Level 4 data, Ampligen’s immune‑modulating mechanism, orphan drug designations, and updated Ebola-focused investor materials.